TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY

Clin. Cancer Res. - (-) - [2018-09-12; online 2018-09-12]

To infer the prognostic value of simultaneous androgen receptor ( Between March 2014 and April 2017, we recruited mCRPC patients (n=168) prior to ARSi in a cohort study encompassing 10 European centres. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA). Targeted CTC RNA-seq allowed the detection of eight Overall, no single In an all-comer cohort, tumour burden estimates and

Bioinformatics Support for Computational Resources [Service]

Clinical Genomics Stockholm [Service]

PubMed 30209161

DOI 10.1158/1078-0432.CCR-18-1943

Crossref 10.1158/1078-0432.CCR-18-1943

pii: 1078-0432.CCR-18-1943